Late-Breaking Science Oral Abstracts I
LB5. Volume of brain saved in patients with a medium distal vessel occlusion stroke treated with endovascular therapy plus best medical treatment versus best medical treatment alone: A sub-analysis of the DISTAL Trial
LB5. 中远端血管闭塞性卒中患者采用血管内治疗联合最佳药物治疗与单纯最佳药物治疗相比所挽救的脑体积：DISTAL试验的亚组分析
SYCAMORE - LB6. The SYCAMORE Study Results: First Randomized, Placebo-Controlled Phase 2 Trial in Symptomatic Cerebral Cavernous Malformation (CCM) Evaluating REC-994
LB6. SYCAMORE研究结果：评估REC-994的首个针对症状性脑海绵状血管畸形（CCM）的随机、安慰剂对照2期试验
EMPHASIS - LB7. Efficacy and Safety of Minocycline in Patients with Acute Ischemic Stroke (EMPHASIS): a randomized control trial
LB7. 米诺环素在急性缺血性卒中患者中的疗效和安全性：随机对照EMPHASIS试验
LB8. Targeting Cerebral Amyloid Angiopathy at its Source: An Amyloid Beta Precursor Protein-Targeted siRNA Reduced Vascular Amyloid Beta and Hemorrhage in Rodent Models
LB8. 从源头靶向脑淀粉样血管病：一种靶向淀粉样前体蛋白的小干扰RNA减少了啮齿动物模型中的血管淀粉样β和出血
Late Breaking Science Oral Abstracts II
LB9. Clinical Benefit of Nerinetide at One Year in Early Window Participants Enrolled in ESCAPE-NEXT
LB9. ESCAPE-NEXT研究中早期入组患者使用Nerinetide一年的临床获益
LB10. Impact of Socioeconomic Status on Quality and Clinical Outcomes in Acute Ischemic Stroke Patients: Findings from Get With The Guidelines®-Stroke
LB10. 社会经济状况对急性缺血性卒中患者质量和临床结局的影响：来自Get With The Guidelines®-Stroke的研究结果
LB11. More Severe Disruption of the Blood-Brain Barrier Predicts Greater Progression of Cerebral Small Vessel Disease
LB11. 血脑屏障更严重的破坏预示着脑小血管病更大的进展
LB12. Efficacy of otaplimastat in cute stroke patients requiring reperfusion therapy standard of care: a pooled analysis of two double-blind, randomized, placebo-controlled studies
LB12. Otaplimastat在需要再灌注治疗标准护理的急性卒中患者中的疗效：两项双盲、随机、安慰剂对照研究的汇总分析
LB13. Stability of flow diverter braids in INSPIRE-A: biomechanical predictors and clinical relevance
LB13. INSPIRE-A中血流导向装置编织体的稳定性：生物力学预测因素和临床相关性
LB14. The Efficacy of Papaverine to Prevent Radial Artery Spasm During Transradial Cerebral Angiography (PASS): A Multicenter Randomized Trial
LB14. 罂粟碱预防经桡动脉脑血管造影期间桡动脉痉挛的有效性：多中心随机PASS试验
LB15. Results Of The First Randomized Controlled Trial Of Intravenous Alteplase Initiated Within 4.5 Hours Of Central Retinal Artery Occlusion (CRAO): The THEIA Study
LB15. 视网膜中央动脉阻塞（CRAO）4.5小时内启动静脉阿替普酶治疗的首个随机对照试验结果：THEIA研究
Late Breaking Science Oral Abstracts III
LB21. Efficacy and Safety of Intra-Arterial Thrombolysis Following Endovascular Reperfusion for Large-Vessel Occlusion Acute Ischemic Stroke: An Individual Patient Data Meta-Analysis of POST-UK and POST-TNK Randomized Trial
LB21. 大血管闭塞急性缺血性卒中血管内再通后动脉内溶栓的有效性和安全性：POST-UK和POST-TN 随机试验的个体患者数据荟萃分析
LB22. Glucagon-Like Peptide-1 Receptor Agonist in Large Vessel Occlusion Stroke Treated by Reperfusion Therapy – a randomized trial
LB22. 胰高血糖素样肽-1受体激动剂在再灌注治疗的大血管闭塞性卒中中的应用——一项随机试验
LB23. Transauricular vagus nerve stimulation decreases inflammatory biomarkers and affects NIHSS in acute ischemic stroke patients: Results from the NUVISTA trial
LB23. 经耳迷走神经刺激降低急性缺血性卒中患者炎症生物标志物水平并影响美国国立卫生研究院卒中量表（NIHSS）评分：NUVISTA试验结果
LB24. Emergency Stroke Unit for Acute Cerebrovascular Events - A multicenter, alternating-week, randomized, controlled trial
LB24. 急性脑血管事件急诊卒中单元——一项多中心、隔周、随机、对照试验
Late Breaking Science Oral Abstracts IV
LB25. Updated results from the multicentric, randomized study of sovateltide (Tycamzzi™) in acute cerebral ischemic stroke patients
LB25. 急性脑缺血性卒中患者中索伐尔泰（Tycamzzi™）多中心随机研究的最新结果
LB26. Comparative Effectiveness of Direct oral Anticoagulants and warfarin in Reduced ejection fraction after stroke (CEDAR)
LB26. 直接口服抗凝剂与华法林在降低卒中后射血分数方面的比较效果：CEDAR研究
LB27. Dementia-Free Survival Differs by Midlife Blood Pressure and Genetic Risk Groups: The Atherosclerosis Risk in Communities (ARIC) Study
LB27. 中年血压和遗传风险组的无痴呆生存率存在差异：社区动脉粥样硬化风险（ARIC）研究
LB28. SPRIN2G-D nomogram: A Reliable Tool to Predict the 90-day Unfavorable Prognosis in Minor Ischemic Stroke Patients Receiving Intravenous Thrombolysis
LB28. SPRIN2G-D列线图：预测接受静脉溶栓治疗的轻型缺血性卒中患者90天不良预后的可靠工具
Late Breaking Science Oral Abstracts V
LB29. Rapid administration of enteral nutrition reduces complications and is non-inferior to conventional administration in acute stroke patients: The Rapid EN Randomized Clinical Trial
LB29. 急性卒中患者快速给予肠内营养可减少并发症且不劣于常规给予方式：快速肠内营养（Rapid EN）随机临床试验
LB30. Cerebral Blood Flow Response to Intrathecal Nicardipine is Associated with Delayed Cerebral Ischemia after Subarachnoid Hemorrhage
LB30. 鞘内注射尼卡地平后脑血流量反应与蛛网膜下腔出血后迟发性脑缺血相关
LB31. Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 hours without thrombectomy: A secondary analysis of the TRACE-3 trial
LB31. 4.5至24小时未进行取栓的缺血性卒中患者梗死生长率及替奈普酶获益情况：TRACE-3试验的二次分析
LB32 Spatio-temporal Progression of Focal Ischemic White Matter Injury
LB32. 局灶性缺血性白质损伤的时空进展
Late Breaking Science Oral Abstracts VI
